Matinas BioPharma Holdings (MTNB) Receivables - Other (2015 - 2023)

Matinas BioPharma Holdings (MTNB) reported Receivables - Other of $4.6 million for Q4 2023, up 5607.3% quarter-over-quarter from $79810.0 in Q3 2015.

Matinas BioPharma Holdings (MTNB) Receivables - Other (2015 - 2023) Analysis & Trends

Matinas BioPharma Holdings (MTNB) has 2 years of Receivables - Other data on file, last reported at $4.6 million in Q4 2023.

Receivables - Other for Q4 2023 came in at $4.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $4.6 million (changed N/A YoY), and the FY2023 annual result was $4.6 million, changed N/A from the prior year.
Receivables - Other grew to $4.6 million in Q4 2023 per MTNB's latest filing, from $79810.0 in the prior quarter.
Over five years, Receivables - Other peaked at $4.6 million in Q4 2023 and troughed at $4.6 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Matinas BioPharma Holdings	4.60 Mn	2.15 Mn	-

Download Data